With vaccines, it's really group immunity.

Read: Vaccines are the only way to beat the epidemic.
Prime Minister Boris Johnson launched britain's plan to combat the outbreak in early March by not being strict, tolerating the slow development of the outbreak and allowing 60 per cent of Britons to recover from illness, thereby achieving mass immunization to control the outbreak.
since then, the word "group immunity" has been in the public eye, causing a stir.
"group immunity" refers to a large proportion of people in the population to cause disease pathogens to develop immunity, the establishment of an immune barrier, the probability of transmission between individuals and individuals reduced, the transmission chain is interrupted, so that they have no immunity of individuals are protected.
(pictured is what is group immunity?) However, mass immunization does not persist.
first, there is no evidence that the new coronapneumonia virus is life-long immune to the virus.
2000, measles, which was declared eliminated in the United States, is a case in point, with another outbreak in 2019 as the number of people vaccinated declines.
second, the coronavirus is a single-stranded RNA virus with cystic membranes.
RNA polymerase lacks proofing function, so its mutation frequency is much higher than that of cell DNA or DNA viruses.
once the viral antigen mutates, the established group immunity will fail.
, such as influenza viruses, often mutate to produce new strains that people can't cope with, leading to an annual flu epidemic.
people know the characteristics of the new coronavirus is limited, the natural immune risk is too large, so take strict control and isolation measures, time-for-space, look forward to the vaccine as soon as possible to develop.
vaccination is the best immunization measure and the best preventive measure to look forward to. On February 21,
, at a press conference held by the State Council's joint prevention and control mechanism for outbreaks, the National Health and Health Commission announced that China currently has five vaccine research and development technology routes in parallel, namely inactivated vaccines, recombinant genetic engineering vaccines, adenovirus vector vaccines, influenza vector vaccines, nucleic acid vaccines.
the development principle of inactivated vaccine is easy to understand, is the whole killing of pathogens directly into a vaccine, retain its antigen characteristics, induce the human body to produce antibodies.
the research and development route of inactivated vaccine is relatively mature, as long as the successful separation and screening of immunogenic qualified and cell-cultured strains, and can be large-scale production.
in addition, inactivated vaccine quality control points and evaluation methods are also relatively clear, and usually have better safety and immunogenicity.
inactivated vaccines in the
are: polio inactivated vaccine, cerebro-inactivated vaccine, hepatitis A inactivated vaccine, rabies vaccine, hand-foot-mouth vaccine, cholera vaccine, haemorrhagic fever vaccine and so on.
one of the technological routes to develop a new crown vaccine is inactivated. On June 23,
, China Pharmaceutical Group's China Bio-New Crown Inactivated Vaccine (Phase III) was approved in the United Arab Emirates, marking the official launch of the world's first international clinical trial of the new crown inactivated vaccine (Phase III).
adenovirus vector vaccine is a vector vaccine using adenovirus as an active ingredient.
also extracted the antigen gene of the new coronavirus, through genetic modification technology, the vaccine drawings through the carrier into the human cell recombined adenovirus.
it is injected into the human body, it induces the immune system to remember the characteristics of the new coronavirus and produces a memory effect to prevent the new coronavirus in case of a real invasion.
the technology is already used in the non-conventional Ebola vaccine.
this is the first of the five technical routes mentioned by the Health and Welling Council in China to conduct human clinical trials of the new crown vaccine.
11 members of Chen Wei's team had been vaccinated as early as February 29. On March 16,
, at 20:18, the adenovirus vector vaccine developed by Chen Wei's team was approved for start-up clinical trials.
nucleic acid vaccine nucleic acid vaccine generally refers to RNA vaccine or DNA vaccine.
coronavirus is a class of single-stranded RNA viruses with cystic membranes, the principle of the nucleic acid vaccine is that, after the gene sequence of the new coronavirus, the gene is fed into human cells by transporting proteins, which are used in cells to synthesize the vaccine protein components with this foreign gene.
is immune protection by expressing proteins in the body and stimulating the body to produce specific immunological responses.
has not yet been approved for the mRNA vaccine or therapeutic products on the market, if the mRNA vaccine is really successful, will have the advantage of crushing the traditional vaccine.
mRNA will be like a chain, can prevent A disease, B disease, C disease ... The chain is chained together to form a long chain, which is equivalent to a multi-link vaccine.
vaccination of this multi-mRNA vaccine can prevent N diseases, vaccination will be very simple and efficient, can be said to bring about a vaccine revolution.
According to the News released in Suzhou on June 26, Suzhou Aibo Biotech Co., Ltd. jointly developed a new coronavirus mRNA vaccine jointly developed by the Military Medical Research Institute of the Academy of Military Sciences and Yunnan Watson Biotechnology Co., Ltd., which was officially approved by the Clinical Trials of the State Drug Administration.
this is the first mRNA vaccine approved for clinical trials in china.
recombinant protein vaccine This technique is to encode the vaccine component of the antigen gene through the vector to a specific microorganism or cell, under certain induced conditions, the expression of a large number of antigen protein, through purification after the preparation of the vaccine.
microbes or cells are easy to culture and can be used in mass production of vaccine ingredients.
the biggest advantage of the recombinant protein vaccine technology route is that it is highly safe and easy to produce on a large scale.
recombinant vaccines in the active vaccine are: hepatitis B vaccine, hepatitis E vaccine, cervical cancer vaccine.
the new crown recombinant protein vaccine jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd., has been approved by the State Drug Administration and entered into clinical trials.
the influenza virus vector vaccine influenza virus vector vaccine vaccine mechanism is: the use of detoxifying influenza virus vaccine as a carrier, load the new coronavirus protein.
the theory that the human body is immune to this influenza virus, but also can be immune to the new crown virus, can be said to be a double-edged sword.
the development of this technology is still in its infancy and no vaccine has yet been introduced.
in the research and development and production process will encounter what kind of problems can not be estimated, there is a great deal of uncertainty.
the new coronavirus is currently in a global pandemic, the need for new crown vaccines in various countries will be hundreds of millions or even billions;
vaccines with different technical routes, which, according to their inherent characteristics, may be applied differently at different stages of the development of the new crown outbreak.
, for example, adenovirus vector vaccines may be the first to be used in emergency, and inactivated and recombinant protein vaccines may be used in large-scale populations at a later stage.
for now, the fastest-growing new crown inactivated vaccine in the country will be possible to market as soon as the end of this year or early next year.
at present, the growth trend of the outbreak of overseas outbreaks is still continuing, and the pressure of my foreign defense importcontinues.
to expand the scope of testing, the entry of personnel to carry out "inspection", do a good job of closed-loop management, to prevent the outbreak rebound.
China! Chinese scientists refuel! China vaccine refueling! Quote document 1, Tang Jiangfeng. Group immunity, current anti-epidemic is not reliable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Why the UK's anti-epidemic strategy has been swerved. Ruiz Jarabo CM, Arias A, Molina Paris C, Briones C, Baranowski E, Escarmis C, E. Duration and fitnessdependencespeciesmemory.J MolBiol, 2003, 315 (3): 285-296.5, Niu Ning. Focus on the new coronavirus and its pathogenic mechanisms. .J. Zhangjiang Science and Technology Review, 2020 (01): 8-10: 6, Taulina. The five technical routes of the research and development of the new crown vaccine are fully analyzed. Beijing Science and Technology Daily, 2020-04-06 (009)7, Kangzhuang, Tang Mei. Development and analysis of the new coronavirus vaccine research and development and analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .